학술논문
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.
Document Type
Article
Author
Manier, Salomon; Huynh, Daisy; Yu J. Shen; Jia Zhou; Yusufzai, Timur; Salem, Karma Z.; Ebright, Richard Y.; Jiantao Shi; Jihye Park; Glavey, Siobhan V.; Devine, William G.; Chia-Jen Liu; Leleu, Xavier; Quesnel, Bruno; Roche-Lestienne, Catherine; Snyder, John K.; Brown, Lauren E.; Gray, Nathanael; Bradner, James; Whitesell, Luke
Source
Science Translational Medicine; 5/10/2017, Vol. 9 Issue 389, p1-13, 13p
Subject
Language
ISSN
19466234
Abstract
The article discusses the oncogenic translation program as an effective therapeutic strategy in multiple myeloma (MM). It cites on the frequently incurable hematological cancer with overactivity of MYC-driven translation program in MM with rocaglates. The article discusses the identification of chemical compounds that disrupt ribosome biogenesis and translation activation in MM.